Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$3.30 USD
+0.08 (2.48%)
Updated Aug 13, 2024 03:41 PM ET
After-Market: $3.34 +0.04 (1.21%) 5:54 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APRE 3.30 +0.08(2.48%)
Will APRE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APRE
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Lags Revenue Estimates
APRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
Other News for APRE
Buy Rating Justified by Aprea Therapeutics’ Financial Health and Innovative Clinical Trials
Wedbush Initiates a Buy Rating on Aprea Therapeutics (APRE)
APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024
Analysts Are Bullish on These Healthcare Stocks: Aprea Therapeutics (APRE), TScan Therapeutics (TCRX)
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update